Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 29:15:650220.
doi: 10.3389/fnins.2021.650220. eCollection 2021.

Polygenic Score Models for Alzheimer's Disease: From Research to Clinical Applications

Xiaopu Zhou  1   2   3 , Yolanda Y T Li  1 , Amy K Y Fu  1   2   3 , Nancy Y Ip  1   2   3
Affiliations
Review

Polygenic Score Models for Alzheimer's Disease: From Research to Clinical Applications

Xiaopu Zhou et al. Front Neurosci. .

Abstract

The high prevalence of Alzheimer's disease (AD) among the elderly population and its lack of effective treatments make this disease a critical threat to human health. Recent epidemiological and genetics studies have revealed the polygenic nature of the disease, which is possibly explainable by a polygenic score model that considers multiple genetic risks. Here, we systemically review the rationale and methods used to construct polygenic score models for studying AD. We also discuss the associations of polygenic risk scores (PRSs) with clinical outcomes, brain imaging findings, and biochemical biomarkers from both the brain and peripheral system. Finally, we discuss the possibility of incorporating polygenic score models into research and clinical practice along with potential challenges.

Keywords: APOE; Alzheimer’s disease; genetics; polygenic hazard score; polygenic risk score; polygenic score; risk prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with one of the authors NI.

Figures

FIGURE 1
FIGURE 1
Summary of polygenic score research on Alzheimer’ disease. (A) Numbers of published papers by year. (B) Proportions of studies by population. (C) Proportions of study participants by ethnic group.
FIGURE 2
FIGURE 2
Proposed hierarchal strategy for Alzheimer’s disease risk screening. Individuals enrolled in a screening task are first examined according to genetic risk as indicated by polygenic risk analysis. Individuals who have relatively high risk and report symptoms are referred for biomarker examination to evaluate amyloid-beta, tau (and p-tau), and neurofilament light polypeptide levels (i.e., the “ATN” panel) in blood or cerebrospinal fluid (CSF). Those who exhibit altered levels of biomarkers are further referred to clinicians for cognitive assessment followed by brain imaging including magnetic resonance imaging and positron emission tomography.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease.
    Bhalala OG, Watson R, Yassi N. Bhalala OG, et al. Int J Mol Sci. 2024 Jan 19;25(2):1231. doi: 10.3390/ijms25021231. Int J Mol Sci. 2024. PMID: 38279230 Free PMC article. Review.
  • Modern Approaches to the Diagnosis of Cognitive Impairment and Alzheimer's Disease: A Narrative Literature Review.
    Ochneva AG, Soloveva KP, Savenkova VI, Ikonnikova AY, Gryadunov DA, Andryuschenko AV. Ochneva AG, et al. Consort Psychiatr. 2023 Mar 31;4(1):53-62. doi: 10.17816/CP716. Consort Psychiatr. 2023. PMID: 38239570 Free PMC article. Review.
  • Stability of polygenic scores across discovery genome-wide association studies.
    Schultz LM, Merikangas AK, Ruparel K, Jacquemont S, Glahn DC, Gur RE, Barzilay R, Almasy L. Schultz LM, et al. HGG Adv. 2022 Jan 21;3(2):100091. doi: 10.1016/j.xhgg.2022.100091. eCollection 2022 Apr 14. HGG Adv. 2022. PMID: 35199043 Free PMC article.
  • Phenotype-informed polygenic risk scores are associated with worse outcome in individuals at risk of Alzheimer's disease.
    Nordengen K, Pålhaugen L, Bettella F, Bahrami S, Selnes P, Jarholm J, Athanasiu L, Shadrin A, Andreassen OA, Fladby T. Nordengen K, et al. Alzheimers Dement (Amst). 2022 Aug 15;14(1):e12350. doi: 10.1002/dad2.12350. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 35991219 Free PMC article.
  • Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.
    de Erausquin GA, Snyder H, Brugha TS, Seshadri S, Carrillo M, Sagar R, Huang Y, Newton C, Tartaglia C, Teunissen C, Håkanson K, Akinyemi R, Prasad K, D'Avossa G, Gonzalez-Aleman G, Hosseini A, Vavougios GD, Sachdev P, Bankart J, Mors NPO, Lipton R, Katz M, Fox PT, Katshu MZ, Iyengar MS, Weinstein G, Sohrabi HR, Jenkins R, Stein DJ, Hugon J, Mavreas V, Blangero J, Cruchaga C, Krishna M, Wadoo O, Becerra R, Zwir I, Longstreth WT, Kroenenberg G, Edison P, Mukaetova-Ladinska E, Staufenberg E, Figueredo-Aguiar M, Yécora A, Vaca F, Zamponi HP, Re VL, Majid A, Sundarakumar J, Gonzalez HM, Geerlings MI, Skoog I, Salmoiraghi A, Boneschi FM, Patel VN, Santos JM, Arroyo GR, Moreno AC, Felix P, Gallo C, Arai H, Yamada M, Iwatsubo T, Sharma M, Chakraborty N, Ferreccio C, Akena D, Brayne C, Maestre G, Blangero SW, Brusco LI, Siddarth P, Hughes TM, Zuñiga AR, Kambeitz J, Laza AR, Allen N, Panos S, Merrill D, Ibáñez A, Tsuang D, Valishvili N, Shrestha S, Wang S, Padma V, Anstey KJ, Ravindrdanath V, Blennow K, Mullins P, Łojek E, Pria A, Mosley TH, Gowland P, Girard TD, Bowtell R, Vahidy FS. de Erausquin GA, et al. Alzheimers Dement (N Y). 2022 Sep 22;8(1):e12348. doi: 10.1002/trc2.12348. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36185993 Free PMC article.
See all "Cited by" articles

References

    1. Adams H. H. H., De Bruijn R. F. A. G., Hofman A., Uitterlinden A. G., Van Duijn C. M., Vernooij M. W., et al. (2015). Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimer’s Dement. 11 1277–1285. 10.1016/j.jalz.2014.12.008 - DOI - PubMed
    1. Ajnakina O., Cadar D., Steptoe A. (2020). Interplay between socioeconomic markers and polygenic predisposition on timing of dementia diagnosis. J. Am. Geriatr. Soc. 68 1529–1536. 10.1111/jgs.16406 - DOI - PMC - PubMed
    1. Altmann A., Scelsi M. A., Shoai M., de Silva E., Aksman L. M., Cash D. M., et al. (2020). A comprehensive analysis of methods for assessing polygenic burden on Alzheimer’s disease pathology and risk beyond APOE. Brain Commun. 2:fcz047. 10.1093/braincomms/fcz047 - DOI - PMC - PubMed
    1. Andrews S. J., Fulton-Howard B., Patterson C., McFall G. P., Gross A., Michaelis E. K., et al. (2020). Mitonuclear interactions influence Alzheimer’s disease risk. Neurobiol. Aging 87 138.e7–138.e14. 10.1016/j.neurobiolaging.2019.09.007 - DOI - PMC - PubMed
    1. Andrews S. J., McFall G. P., Booth A., Dixon R. A., Anstey K. J. (2019). Association of Alzheimer’s disease genetic risk loci with cognitive performance and decline: a systematic review. J. Alzheimer’s Dis. 69 1109–1136. 10.3233/JAD-190342 - DOI - PubMed

LinkOut - more resources